Pathogenetic Aspects of Bronchial Asthma Phenotyping
- Authors: Byalovskiy Y.Y.1, Glotov S.I.1, Rakitina I.S.1, Ermachkova A.N.2
-
Affiliations:
- Ryazan State Medical University
- City Polyclinic No. 12
- Issue: Vol 32, No 1 (2024)
- Pages: 145-158
- Section: Reviews
- Submitted: 01.02.2023
- Accepted: 11.07.2023
- Published: 07.04.2024
- URL: https://journals.eco-vector.com/pavlovj/article/view/181606
- DOI: https://doi.org/10.17816/PAVLOVJ181606
- ID: 181606
Cite item
Abstract
INTRODUCTION: During a many-year history of its study, bronchial asthma (BA) has gone through the stages of numerous classifications. The introduction of specific biological therapy of BA permitted to speak about the phenotypes of the disease.
AIM: Presentation of the main pathophysiological mechanisms for isolation of endotypes and phenotypes of BA.
The diagnosis of phenotype of BA is based on the pathophysiological mechanisms of its development, which permit to evaluate the dynamics of the disease, make the diagnosis and predict the course of the disease. The most complicated aspect of BA phenotyping is severe forms of the disease characterized by a combination of different phenotypes. This impedes evaluation of specific pathogenetic mechanisms and administration of the optimal therapy for the patient.
CONCLUSION: The diagnosis of BA phenotypes permits to identify specific pathogenetic mechanisms and thereby personalize the treatment.
Keywords
Full Text
About the authors
Yuriy Yu. Byalovskiy
Ryazan State Medical University
Author for correspondence.
Email: b_uu@mail.ru
ORCID iD: 0000-0002-6769-8277
MD, Dr. Sci. (Med.), Professor
Russian Federation, RyazanSergey I. Glotov
Ryazan State Medical University
Email: sergeyglot@mail.ru
ORCID iD: 0000-0002-4445-4480
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, RyazanIrina S. Rakitina
Ryazan State Medical University
Email: rakitina62@gmail.com
ORCID iD: 0000-0002-9406-1765
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, RyazanAnna N. Ermachkova
City Polyclinic No. 12
Email: anna.vyunova@bk.ru
ORCID iD: 0000-0002-2770-3414
Russian Federation, Ryazan
References
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2023 [Internet]. Available at: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023- Full-Report-2023-WMS.pdf. Accessed: 2023 February 01.
- Chuchalin AG, Avdeev SN, Aisanov ZR, et al. Federal guidelines on diagnosis and treatment of bronchial asthma. Pulmonologiya. 2022;32(3):393–447. (In Russ). doi: 10.18093/0869-0189-2022-32-3-393-447
- The Global Asthma Report 2022. Int J Tuberc Lung Dis. 2022;26(Suppl 1): 1–104. doi: 10.5588/ijtld.22.1010
- Klinicheskiye rekomendatsii. Bronkhial’naya astma. 2021 [Internet]. Available at: https://cr.minzdrav.gov.ru/recomend/359_2. Accessed: 2023 February 01. (In Russ).
- Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;129(4):1493–503. doi: 10.1172/jci124611
- Chung KF. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med. 2018;24(1):4–10. doi: 10.1097/mcp.0000000000000434
- Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–8. doi: 10.1164/ajrccm.160.3.9812110
- Shaw DE, Sousa AR, Fowler SJ, et al.; U-BIOPRED Study Group. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2016;46(5):1308–21. doi: 10.1183/13993003.00779-2015
- Loza MJ, Djukanovic R, Chung KF, et al. Validated and longitu- dinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res. 2016;17(1):165. doi: 10.1186/s12931-016-0482-9
- Chung KF, Dixey P, Abubakar–Waziri H, et al. Characteristics, phenotypes, mechanisms and management of severe asthma. Chin Med J (Engl). 2022;135(10):1141–55. doi: 10.1097/cm9.0000000 000001990
- Guo Z, Wu J, Zhao J, et al. IL-33 promotes airway remodeling and is a marker of asthma disease severity. J Asthma. 2014;51(8):863–9. doi: 10.3109/02770903.2014.921196
- Al-Sajee D, Sehmi R, Hawke TJ, et al. The expression of IL-33 and TSLP and their receptors in asthmatic airways following inhaled allergen challenge. Am J Respir Crit Care Med. 2018;198(6):805–7. doi: 10.1164/rccm.201712-2468le
- Yang Q, Ge MQ, Kokalari B, et al. Group 2 innate lymphoid cells mediate ozone-induced airway inflammation and hyperrespon- siveness in mice. J Allergy Clin Immunol. 2016;137(2):571–8. doi: 10.1016/j.jaci.2015.06.037
- Chen R, Smith SG, Salter B, et al. Allergen-induced Increases in Sputum Levels of Group 2 Innate Lymphoid Cells in Subjects with Asthma. Am J Respir Crit Care Med. 2017;196(6):700–12. doi: 10.1164/rccm.201612-2427oc
- Hirose K, Iwata A, Tamachi T, et al. Allergic airway inflammation: key players beyond the Th2 cell pathway. Immunol Rev. 2017;278(1): 145–61. doi: 10.1111/imr.12540
- Syabbalo N. Biomarkers for Diagnosis and Management of Eosinophilic Asthma. Ann Clin Med Res. 2020;1(1):1003.
- Guo L, Huang Y, Chen X, et al. Innate immunological function of TH2 cells in vivo. Nat Immunol. 2015;16(10):1051–9. doi: 10.1038/ni.3244
- Persson C. Lysis of primed eosinophils in severe asthma. J Allergy Clin Immunol. 2013;132(6):1459–60. doi: 10.1016/j.jaci.2013.09.036
- Cayrol C, Girard J–P. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281(1):154–68. doi: 10.1111/imr.12619
- Fanning LB, Boyce JA. Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol. 2013;111(3):155–62. doi: 10.1016/j.anai. 2013.06.031
- Kim BS, Wang K, Siracusa MC, et al. Basophils promote innate lymphoid cell responses in inflamed skin. J Immunol. 2014;193(7): 3717–25. doi: 10.4049/jimmunol.1401307
- Samitas K, Delimpoura V, Zervas E, et al. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev. 2015; 24(138):594–601. doi: 10.1183/16000617.00001715
- Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. 2013;131(6):1504–12. doi: 10.1016/j.jaci.2013.01.035
- Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lympho- poietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016; 137(5):1566–76.e5. doi: 10.1016/j.jaci.2015.10.020
- Kuruvilla ME, Lee FE–H, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol. 2019;56(2):219–33. doi: 10.1007/s12016-018-8712-1
- James B, Milstien S, Spiegel S. ORMDL3 and allergic asthma: From physiology to pathology. J Allergy Clin Immunol. 2019;144(3):634–40. doi: 10.1016/j.jaci.2019.07.023
- Pua HH, Ansel KM. MicroRNA regulation of allergic inflammation and asthma. Curr Opin Immunol. 2015;36:101–8. doi: 10.1016/j.coi.2015.07.006
- Yu X, Wang M, Li L, et al. MicroRNAs in atopic dermatitis: A systematic review. J Cell Mol Med. 2020;24(11):5966–72. doi: 10.1111/jcmm.15208
- Lacedonia D, Palladino GP, Foschino–Barbaro MP, et al. Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma-COPD overlap syndrome phenotype. Int J Chron Obstruct Pulmon Dis. 2017;12:1811–7. doi: 10.2147/copd.s130616
- Boudewijn IM, Roffel MP, Vermeulen CJ, et al. A Novel Role for Bronchial MicroRNAs and Long Noncoding RNAs in Asthma Remission. Am J Respir Crit Care Med. 2020;202(4):614–8. doi: 10.1164/rccm.201908-1610le
- Li X, Ye S, Lu Y. Long non-coding RNA NEAT1 overexpression associates with increased exacerbation risk, severity, and inflammation, as well as decreased lung function through the interaction with microRNA-124 in asthma. J Clin Lab Anal. 2020;34(1):e23023. doi: 10.1002/jcla.23023
- Ramelli SC, Gerthoffer WT. MicroRNA Targets for Asthma Therapy. Adv Exp Med Biol. 2021;1303:89–105. doi: 10.1007/978-3-030- 63046-1_6
- Li W, Gao P, Zhi Y, et al. Periostin: Its role in asthma and its potential as a diagnostic or therapeutic target. Respir Res. 2015;16(1):57. doi: 10.1186/s12931-015-0218-2
- Bentley JK, Chen Q, Hong JY, et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol. 2014;134(6):1433–42. doi: 10.1016/j.jaci.2014.05.029
- Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11. doi: 10.1186/1471-2466-13-11
- Zaihra T, Walsh CJ, Ahmed S, et al. Phenotyping of difficult asthma using longitudinal physiological and biomarker measurements reveals significant differences in stability between clusters. BMC Pulm Med. 2016;16(1):74. doi: 10.1186/s12890-016-0232-2
- Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: A systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290–300. doi: 10.1016/s2213-2600(15)00050-8
- Plaza V, Crespo A, Giner J, et al. Inflammatory Asthma Phenotype Discrimination Using an Electronic Nose Breath Analyzer. J Investig Allergol Clin Immunol. 2015;25(6):431–7.
- Van der Sche MP, Palmay R, Cowan JO, et al. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy. 2013;43(11):1217–25. doi: 10.1111/cea.12147
- Pavord I, Bahmer T, Braido F, et al. Severe T2-high asthma in the biologics era: European experts’ opinion. Eur Respir Rev. 2019;28(152):190054. doi: 10.1183/16000617.0054-2019